surmount-1 tirzepatide weight loss percent 72 weeks reduction over time in tirzepatide‐treated participants by early weight response: Post hoc analysis in SURMOUNT‐1 - Ard - 2025 - Diabetes, Obesity and Metabolism SURMOUNT-1 Trial - Cardionerds Twitter

Semaglutide is a GLP-1 receptorbased therapy that works through pathways involved in appetite regulation, digestion, and glucose metabolism

[1] These results support a selective growth hormone response in that study

Fueling and imaging brain activation

JAAPA Off J Am Acad Physician Assist

The added targets generally correlate with larger weight reductions in trials

Author HealthCert Education As GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) become more widely prescribed for type 2 diabetes and weight management, general practitioners are increasingly likely to encounter patients experiencing gut-related side effects